Zymeworks Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary

Zymeworks (Nasdaq: ZYME) has announced its participation in six major healthcare investor conferences throughout November and December 2024. The clinical-stage biotechnology company will engage in various activities including one-on-one meetings, fireside chats, and panel discussions. The conferences include the UBS Global Healthcare Conference, Stifel Healthcare Conference, Jefferies London Healthcare Conference, Piper Sandler Healthcare Conference, Citi's Global Healthcare Conference, and the Evercore HealthCONx Conference. At Citi's conference, management will participate in a panel discussion on 'Novel Antibody Mechanisms in Oncology'.

VANCOUVER, British Columbia, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences:

• UBS Global Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings on November 12 in Rancho Palos Verdes, CA.
• Stifel 2024 Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on November 19 at 4:10 pm Eastern Time (ET) in New York, NY.
• Jefferies London Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings on November 20-21 and a fireside chat on November 20 at 2:30 pm Greenwich Mean Time in London, UK.
• Piper Sandler 36^th Annual Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and present on December 3 in New York, NY.
• Citi's 2024 Global Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and a panel discussion titled: ‘Novel Antibody Mechanisms in Oncology’ on December 3 at 3:15 pm ET in Miami, FL.
• 7^th Annual Evercore HealthCONx Conference: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on December 4 at 7:55 am ET in Coral Gables, FL.

About Zymeworks Inc.
Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers. A Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC) has been accepted and granted Priority Review. A BLA has also been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. If approved, zanidatamab would be the first HER2-targeted treatment specifically approved for BTC in the U.S. and China.

Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are now actively recruiting. In addition to Zymeworks’ pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.

Contacts:

Investor Inquiries:

Shrinal Inamdar
Director, Investor Relations
(604) 678-1388 
ir@zymeworks.com 

Media Inquiries:

Diana Papove
Senior Director, Corporate Communications
(604) 678-1388 
media@zymeworks.com

FAQ

What investor conferences will Zymeworks (ZYME) attend in November 2024?

In November 2024, Zymeworks will attend the UBS Global Healthcare Conference (Nov 12), Stifel Healthcare Conference (Nov 19), and Jefferies London Healthcare Conference (Nov 20-21).

What events will Zymeworks (ZYME) participate in during December 2024?

In December 2024, Zymeworks will participate in Piper Sandler Healthcare Conference, Citi's Global Healthcare Conference, and Evercore HealthCONx Conference, all featuring one-on-one meetings and presentations.

What panel discussion will Zymeworks (ZYME) participate in at Citi's 2024 Global Healthcare Conference?

Zymeworks will participate in a panel discussion titled 'Novel Antibody Mechanisms in Oncology' on December 3 at 3:15 pm ET at Citi's 2024 Global Healthcare Conference in Miami.

Where will the Jefferies Healthcare Conference 2024 featuring Zymeworks (ZYME) take place?

The Jefferies Healthcare Conference featuring Zymeworks will take place in London, UK, on November 20-21, 2024.